cyrilzakka/clinical-trials huggingface dataset:
NOSOcomial COVID-19 in ICU (NOSOCOVID)

The current global pandemic at COVID-19 is a major public health issue. Transmission of the virus is primarily through direct and close person-to-person contact. The protection of health care personnel and the limitation of transmission of nosocomial COVID is paramount. Protective measures have already shown their effectiveness in limiting the spread of the virus: the use of masks, the wearing of protective gowns, the wearing of protective eyewear, social and physical distancing. A recent U.S. study (Rhee et al. JAMA 2020) reported a very low incidence of 1.7% of nosocomial COVID, but this was achieved with the application of rigorous infection risk management protocols. In addition to the widespread use of masks and protective measures, dedicated COVID units had been created, with air treatment. The implementation of these dedicated units requires the mobilization of considerable human and material resources, which is not feasible in all hospitals over the long term.

In view of the second wave of the epidemic in France, with the rising numbers of new cases of COVDI-19 admitted to intensive care units since the end of the summer 2020, it is essential to organize the intensive care units to ensure the protection of personnel and limit the risk of nosocomial COVID-19, while continuing to care for non-COVID patients.

In Intensive Care unit (ICU) at the Nantes University Hospital, a strict protocol for the management of suspected or confirmed COVID patients has been in place since early september 2020. The objective of this study is to evaluate the effectiveness of this protocol for managing the infectious risk of SARS-COV-2 on the incidence of nosocomial COVID in patients admitted in ICU. The secondary objectives are to evaluate the incidence of nosocomial-associated COVIDs contracted by caregivers, and the incidence of asymptomatic positive SARS-CoV-2 cases in ICU.

All patients admitted in our ICU since august 2020 were enrolled in the study, after they have been informed and given their consent for their participation in this observational study. Data will be collected computerized patient records by the clinicians in charge of the patient.

Because of variants emergence, the investigators decided to had a second period from march to july. The investigators anticipate an inclusion of approximately 1000 patients.

In an observational study, there is no risk to the patient

Eligibility Criteria:
Inclusion Criteria:

* All Patients admitted in ICU during the inclusion period (Nantes University Hospital)
* AND all Healthcare workers working in ICU during the inclusion period (Nantes University Hospital)

Exclusion Criteria:

* Refusal to participate in research
Effect of IV Infusion of Lidocaine Compared to IV Infusion of Dexmedetomidine on Proinflammatory Cytokines

This study is designed to compare between intravenous infusion of dexmedetomidine and intravenous infusion of lidocaine in reduction of proinflammatory cytokines as IL-6 and TNF-α, some stress reactions (serum insulin and serum lactate),and postoperative analgesic requirements in patients undergoing surgery for pelviabdominal cancers.

Cancer patients who undergo surgery face many sources of stress. Surgery causes major cytokine and neuroendocrinal changes like increased levels of catecholamine and steroid hormones and other metabolic consequences .This stress response is considered a defense mechanism important for developing resistance to noxious insults.

The cytokine cascade caused by surgical stimulation is complex with various effects on the injured host. Increased production of proinflammatory cytokines from the site of injury causes many systemic changes such as metabolic derangements and hemodynamic instability. Some released cytokines like tumor necrosis factor alpha (TNF-α) and Interleukin 6(IL-6) can cause long lasting hyperalgesia. These proinflammatory cytokines change pain signal transmission through cytokine induced release of some neuroactive substances like nitric oxide, oxygen free radicals and excitatory amino acids. On the other hand anti-inflammatory cytokines are also released during inflammation to counteract these effects and keep balance.

Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that has sedative, analgesic, anesthetic-sparing properties with no respiratory depression. Its anti-inflammatory effects are being studied.

Intravenous lidocaine can be used in management of chronic pain. Lidocaine has anti-inflammatory properties and is capable of reducing postoperative analgesic requirements and the length of hospitalization.

The effect of both drugs on proinflammatory cytokines and stress response will be assessed

Eligibility Criteria:
Inclusion Criteria:

* American society of anesthesia (ASA) Physical Status classification:

ASA II physical status.

* Age between 18 to 60 years old.
* Patients who will undergo major pelviabdominal surgery.

Exclusion Criteria:

* Patient refusal.
* Allergy to local anesthetics.
* Cognitive disorders.
* uncontrolled diabetes or hypertension.
HCC Patient Preferences in Japan

This non-interventional cross-sectional online survey will evaluate preferences among patients with self-reported HCC. The survey will ask patients to express their preferences regarding descriptions of HCC treatments, which will include sorafenib (which will be described as 'oral anti-cancer therapy'), repeated transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). Please note that all interventions that patients may have received before completing this online survey were given regardless of their participation in this survey. Questions also include asking patients to rank various treatment characteristics (e.g., mechanism of action, risk of adverse effects, etc.) relative to each other. The ultimate goal is to better understand patient perceptions of these treatments and to provide evidence to help in patients' and physicians' treatment decision-making in HCC.


Eligibility Criteria:
Inclusion Criteria:

The following eligibility criteria will be used:

* Have a diagnosis of HCC
* Are \> 20 years of age
* Reside in Japan
* Are able to read and understand Japanese to provide informed consent and complete the survey instrument

Exclusion Criteria:

None are currently considered
Telephone-based Cognitive Behavioral Therapy for Bariatric Surgery Patients: A Pilot Study

Bariatric surgery is the most effective treatment for patients with extreme obesity. Psychological interventions are not routinely offered in Bariatric Surgery Programs. Preliminary evidence suggests that Cognitive Behavioral Therapy (CBT) might be effective in reducing binge eating and improving surgical outcomes. The current study will examine whether the addition of telephone-based CBT (Tele-CBT) to the usual standard of care is more effective than the usual standard of care alone, and whether it is more effective when delivered prior to or following bariatric surgery.

Preliminary research suggests that CBT might be effective in reducing eating pathology and improving surgical outcomes.

However, previous studies have examined group-based CBT delivered in person, and most patients cannot feasibly attend weekly therapy appointments at the hospital. Telephone-based CBT offers greater convenience because the service can be delivered during the evening and weekends, and eliminates the need to leave work and travel to hospital appointments. No published studies have examined the effectiveness or feasibility of telephone-based CBT for bariatric surgery patients. This study will examine the effectiveness of Tele-CBT as an adjunctive treatment to the usual standard of care in bariatric surgery patients.

Eligibility Criteria:
Inclusion Criteria:

* Fluent in English
* Have access to telephone and computer with internet access
* Have the capacity to provide informed consent

Exclusion Criteria:

* Active suicidal ideation
* Serious mental illness
* Active severe depression
* Active severe anxiety
* Active post traumatic stress disorder
The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics

This study will be the First Time in Human Study (FTIH) aiming to assess the safety and tolerability of GW805858 for both single and repeat dose. The study also aims to assess safety and tolerability in mild asthmatic subjects as well as healthy volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Men or women of non-child bearing potential, aged between 18 and 60 years of age inclusive.
* Body weight = 50 kg (110 lbs) for men and = 45 kg for women and Body Mass Index (BMI) within the range 19.0-30.0 kg/m2 inclusive.
* The subject is a current non-smoker who has not used any tobacco products in the last year.
* A signed and dated written informed consent is obtained for the subject.
* The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
* If asthmatic, the subject must be a clinically stable asthmatic.

Exclusion Criteria:

* The subject has a history of allergy to ingredients within the inhaler.
* The subject has received an investigational drug or participated in any other research trial within 30 days, prior to the first dose of current study medication.
* The subject has used prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 14 days prior to the first dose of study medication.
* The subject has an average weekly alcohol intake of greater than 21 units if male or 14 units if female.
* The subject has any history of breathing problems (e.g. history of asthmatic symptoms).
* The subject is infected with the hepatitis B, hepatitis C, or HIV virus.
* The subject has had a respiratory tract infection or worsening of asthma within 4 weeks of the start of the study.
* The subject has a past or present disease, which as judged by the Investigator, may affect the outcome of this study.
* The subject has a history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxia seizures.
* The subject has taken inhaled, nasal or dermal steroids within 4 weeks or oral steroids within 8 weeks of the start of the study.
* The subject is unable to abstain from other drugs that may interfere with the conduct of the study.
* The subject has ongoing rhinitis that requires treatment.
Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy

To assess the pain relief and the hemodynamic stability of ropivacaine with epinephrine in BABA endoscopic and robotic thyroidectomy.

Diluted ropivacaine with epinephrine is injected into the subcutaneous space to relieve pain and reduce bleeding during procedures. The synergistic effect of ropivacaine with epinephrine can contribute to patients' welfare, such as relieving pain and structuring the hemodynamic stability.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of thyroid neoplasm or benign goiter
* Scheduled for BABA endoscopic or robotic thyroidectomy

Exclusion Criteria:

* Completion thyroidectomy
* Modified radical neck dissection
* Allergy history
* Stroke history
* Uncontrolled hypertension
* Uncontrolled diabetes
* Coagulopathy
* Severe cardiovascular disease
* Severe pulmonary disease
* Chronic kidney disease
* Pregnant
Monoclonal Antibody-based Multipurpose Microbicides

The purpose of this project is to explore women's thoughts, opinions, and ideas about vaginal products. The investigators will ask women to help design the best strategy for applying a vaginal product using a specific kind of applicator. The investigators want to identify designs that women think would be easy to prepare and insert. Women's thoughts and opinions will help researchers develop new products called microbicides that may protect against HIV and other sexually transmitted diseases, that are easy to use, and that will be acceptable to women who use them. If researchers can make products that are easy to use and that women like to use, the products will be used more often, and more infections will be prevented.

Women who enroll in the project will either participate in a focus group with approximately 3-7 other women or a one-on-one cognitive interview. All participants will complete a brief questionnaire. Some women may enroll in both stages.

Each focus group will take approximately 1.5-2.5 hours. Group leaders will talk to women about their experiences using vaginal products and will provide participants with study products to look at and touch. All participants will be asked to come up with ideas of how to make the products easy to use and acceptable to women who use them. Group leaders will encourage discussion about the different designs. After this, group leaders will talk about a specific type of microbicide and ask women about their opinions. In particular, researchers and participants will talk about the language that would be best understood by women who would use these products or be in studies to evaluate them.

Each cognitive interview will take approximately 1.5-2.5 hours. Each participant will be asked about different product designs and application instructions, and will be asked her thoughts, opinions, and potential concerns about each. She will also evaluate sample language that will be used to help women understand the products and how to use them.


Eligibility Criteria:
Inclusion Criteria:

Women who:

* are between the ages of 18 and 45 at prescreening
* report vaginal sex with a man in the past 12 months at prescreening
* report negative pregnancy status and no intention to become pregnant during the course of the study
* report negative or unknown HIV status, and
* are willing and able to provide informed consent.

Exclusion Criteria:

Women who:

* self-report being pregnant, or intention to become pregnant during the course of the study
* self-report being HIV-positive
* self-report an allergy or sensitivity to vaginal contraceptive film (VCF), nonoxynol-9 (N9), or product(s) containing N9
* are unable or unwilling to give informed consent, or
* have any condition that, in the opinion of the project leader or principle investigator, would compromise the participant's ability to participate in the study.
SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting

The proportion of asymptomatic carriers of SARS-CoV-2 remains elusive, so the potential benefit of systematic screening during the SARS-CoV-2-pandemic is controversial. We investigate the proportion of asymptomatic inpatients who were identified by systematic screening for SARS-CoV-2 upon hospital admission.

Adult patients admitted to the University Hospital Basel from 01.04.-14.06.2020 were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.

Each patient screened during the study period was retrospectively classified symptomatic or asymptomatic for COVID-19 based on medical chart review.


Eligibility Criteria:
Inclusion Criteria:

* The patient population is defined as all adult patients hospitalized in the University Hospital Basel from April 1st, 2020 to June 14th, 2020.

Exclusion Criteria:

* Outpatients
* Patients with SARS-CoV-2 screening in the outpatient test center
* Patients with a SARS-CoV-2 test more than 72 hours before hospital admission
* Test not performed (for any reason)
A Registry Study of Patients Hospitalized With Confirmed COVID-19

The design of this registered study aims to evaluate the efficacy and safety of Paxlovid in the treatment of hospitalized COVID-19 patients, and to explore factors related to the efficacy and safety of Paxlovid.


Eligibility Criteria:
Inclusion Criteria:

1. Confirmed diagnosis of COVID-19 infection.
2. Presence of at least one high-risk factor, including age ≥60 years, diabetes, hypertension, cardiovascular disease, stroke, chronic liver or kidney disease, cancer, history of smoking or obesity.

Exclusion Criteria:

* No specific exclusion criteria in this study.
Role of Metabolites in Nicotine Dependence (3) - 6

The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.

Previous studies have shown that cotinine, a metabolite of nicotine, antagonizes the beneficial effects of the nicotine patch in redugin withdrawal symptoms. Studies have also shown that cotinine enhances serotonin levels. This study examined the effects of several doses of a 5HT3 antagonist, ondanstron, in combination with the nicotine patch. This medication has been observed to reduce nicotine withdrawal symptoms in rats. These effects were compared to the nicotine patch alone. The results of this study produced some modest effects showing that the 8mg dose of ondansetron suppressed tobacco withdrawal symptoms to a greater extent than the nicotine patch alone.

Eligibility Criteria:
Inclusion Criteria:

Male/Female subjects ages 21-45 years inclusive, with a smoking history of at least 15 cigarettes daily (greater than or equal to 50) for at least 1 yr. Subject is in good health as verified by medical history, screening examination, and screening laboratory tests as outlined above. Subject has provided written informed consent to participate in the study and is motivated to stop smoking. Subject has experienced at least 4 withdrawal symptoms upon abstinence.

Exclusion Criteria:

History of myocardial infarction, angina pectoris, sustained or episodic cardiac arrhythmias, symptomatic peripheral vascular disease, current peptic ulcer disease or any other medical condition which the physician investigator deems inappropriate for subject participation. Insulin-dependent diabetes. Pregnant or lactating, or not using adequate birth control methods. Requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent psychiatric history (less than 1yr). Chronic use of systemic steroids or antihistamines. Abuse of alcohol or any other recreational or prescription drug (more than 3 drinks per day or 21 drinks per wk). use of any other nicotine products, including smokeless tobacco, cigars and nicotine replacement products. Inability to fulfill all scheduled visits and examination procedures throughout the study period. History of schizophrenia or manic depressive disorder. Recent history of other psychiatric illness (less than 1yr since last episode of major depressive episode).
Hippocampal Neurogenesis in Human Subjects

This study is being done to measure the number of brain cells that grow in the brain throughout our lives while determining an effective way to complete this with an MRI (Magnetic Resonance Imaging) scanner. The number of these brain cells may be affected by cocaine use. Researchers are trying to understand the long-term effects of cocaine use on the brain.

New neurons are generated through the process of neurogenesis. Although most active during pre-natal development, neurogenesis persists throughout the human lifespan. In adulthood, neurogenesis occurs predominantly in the subgranular zone of the hippocampal dentate gyrus. A highly novel methodology using Magnetic Resonance Spectroscopy (MRS) has recently been developed to measure the formation of hippocampal newborn stem cells in the human brain. We propose to assess Neural Progenitor Cells (NPCs) in the neuropsychiatric disorder cocaine dependence, a chronic disease process associated with pathology of the hippocampus and impaired neurogenesis. In addition, we will assess other measures associated with neurogenesis, including hippocampal (dentate gyrus) cerebral blood volume (CBV) using Vascular-Space-Occupancy (VASO) Magnetic Resonance Imaging. We predict that newborn hippocampal cells \[or neuronal progenitor cells (NPCs\] will be attenuated in recently using cocaine-addicted participants relative to abstinent and control participants, and that these changes will be paralleled by changes in CBV. In this pilot study, we will assess for these changes in cocaine-addicted subjects who are actively using cocaine and those who are recently abstinent (three to six months) as well as age-, race-, and gender-similar control participants.

Eligibility Criteria:
Inclusion Criteria:

* Cocaine-dependence (patient population) or no cocaine-dependence (control population)

Exclusion Criteria:

* Other medical or psychiatric disorders that may effect neural functioning
* Medications that may effect neural functioning
Comparison Between Two Coronally Positioned Flap With Connective Tissue

The aim of this study is to evaluate the effectiveness of total root coverage between two coronally positioned flap technique in Miller recession Class I and II, in patients attending at "Universidad El Bosque" dental school clinics.

This is a blind, randomized controlled clinical trial.

Eligibility Criteria:
Inclusion Criteria:

* Class I and II Miller recessions showing a recession depth ≥ 2 mm.
* Recessions isolated and / or maximum continuous two teeth.
* Recessions in incisors, canines and premolars
* Patients 20 to 60 years old.

Exclusion Criteria:

* Systemic compromise, that contraindicates any periodontal surgical procedure.

  * Warfarin medication.
  * Uncontrolled diabetes mellitus with glycosylated hemoglobin ≥ 8
  * Chronic steroid therapy (dose of 7.5 mg/ day for more than 14 days)
  * HIV-AIDS infection with CD4 counts \<200.
  * Immunosuppression.
* Recessions molars not be taken into account in the study.
* Patients who have used antibiotics one month prior to the surgical procedure.
* Pregnancy.
* Active smoker.
* Patients with a history of periodontal surgery at the recession area that has taken place in the last three months.
* Severe dental malposition, teeth rotation, versions teeth root coverage that contraindicates surgery.
* Non carious cervical lesions or caries where is not visible the cemento- enamel junction (CEJ).
* Active inflammation that contraindicates surgical procedure of the recession.
* Active Orthodontics
The Role of Genetic Factors in the Development of Atopic Dermatitis in the Kazakh Population

This is a GWAS study that aims to identify possible candidate genes associate to atopic dermatitisby exploring single nucleotide polymorphism (SNP) in a group of atopic dermatitis, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with atopic dermatitis

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Eligibility Criteria:
Inclusion Criteria:

* Persons with various forms of a confirmed diagnosis of atopic dermatitis;
* The age of the patients is from 18 to 45+ years;
* Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs.
* Persons who are able and willing to provide written informed consent;
* Persons capable and willing to comply with the research protocol;

Exclusion Criteria:

* Persons under the age of 18;
* Patients with severe concomitant systemic diseases, including cardiovascular, respiratory, hepatic and renal failure
* Patients with severe infectious processes (sepsis, abscess, hepatitis B and C, HIV)
* Persons with mental illness.
* Persons taking corticosteroid drugs, immunosuppressants within the last month;
* Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
* Pregnant or lactating women;
* Tuberculosis of any localization in the active phase and in history;
* Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
* Severe and decompensated course of endocrine diseases;
* Autoimmune diseases;
* Systemic diseases;
* Oncological diseases;